Ritlecitinib

Uses

Product Name: Ritlecitinib
CAS No.: 1792180-81-4
Chemical Name: Ritlecitinib
Synonyms: Ritlecitinib;PF-06651600;CS-2733;EOS-61890;Ritlectinib;Litoxetine (base);Litaxitinib (base);Ritlecitinib (PF-06651600);Ritlecitinib, 10 mM in DMSO;PF-06651600;PF 06651600;PF06651600
CBNumber: CB23142473
Molecular Formula: C15H19N5O
Formula Weight: 285.34
MOL File: 1792180-81-4.mol

More

Less

Ritlecitinib Property

Density: 1.272±0.06 g/cm3(Predicted)
storage temp.: room temp
solubility: DMSO:100.0(Max Conc. mg/mL);350.4(Max Conc. mM)
H2O:5.0(Max Conc. mg/mL);17.5(Max Conc. mM)
form: powder
pka: 13.03±0.50(Predicted)
color: white to beige
Water Solubility: H2O: 5mg/mL, clear (warmed)
InChI: InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1
InChIKey: CBRJPFGIXUFMTM-WDEREUQCSA-N
SMILES: C(N1C[C@H](NC2N=CN=C3NC=CC3=2)CC[C@@H]1C)(=O)C=C

More

Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

More

Less

N-Bromosuccinimide Price

Sigma-Aldrich

Product number: PZ0316
Product name: PF-06651600
Purity: ≥98% (HPLC)
Packaging: 5MG
Price: $111.15
Updated: 2025/07/31

Sigma-Aldrich

Product number: PZ0316
Product name: PF-06651600
Purity: ≥98% (HPLC)
Packaging: 25MG
Price: $340.1
Updated: 2025/07/31

Usbiological

Product number: 462323
Product name: PF-06651600
Packaging: 1mg
Price: $319
Updated: 2021/12/16

Usbiological

Product number: 474159
Product name: PF06651600
Packaging: 100mg
Price: $2315
Updated: 2021/12/16

ChemScene

Product number: CS-0020243
Product name: Ritlecitinib
Purity: 99.98%
Packaging: 5mg
Price: $80
Updated: 2021/12/16

More

Less

Ritlecitinib Chemical Properties,Usage,Production

Uses

Looking at the history of alopecia areata drug development, ritlecitinib is the second mature drug for treating alopecia areata. It is a kinase inhibitor. Unlike the first drug, Olumiant, ritlecitinib is approved not only for adult patients but also for adolescents aged 12 and above.

Description

Ritlecitinib, a dual JAK3/TEC inhibitor, was granted FDA breakthrough status for treating alopecia areata (autoimmune-induced hair loss) in September 2018. Promising phase 3 trial results in alopecia areata were reported by Pfizer in August 2021, placing it in competition with Lilly/Incyte’s Olumiant. It is also used in clinical studies to treat vitiligo, rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. Ritlecitinib achieved high JAK3 selectivity via covalent interaction with a unique cysteine residue (Cys909) in the catalytic domain.

Characteristics

Primary targets: JAK3/TEC
Class: non-receptor tyrosine kinase
Treatment: alopecia areata (phase III)
Protein binding = 14%

Biochem/physiol Actions

PF-06651600 is a potent and selective JAK3 inhibitor.

Pharmacokinetics

Ritlecitinib exhibited low clearance in rats and dogs, contributing to its good oral bioavailability (85% in rats and 109% in dogs). Its lower oral bioavailability in monkeys (56%) primarily resulted from its fast clearance. The pharmacokinetic properties are directly linked to its stability in hepatocytes and whole blood, demonstrating the power of in vitro assays to predict in vivo pharmacokinetic parameters. The good oral bioavailability obtained from rats and dogs was a combination of high passive permeability, high aqueous solubility (>2 mg/mL), and low hepatic clearance. Ritlecitinib underwent CYP3A4-mediated oxidation of the acrylamide and piperidine ring and glutathione conjugated with the acrylamide. Allometric scaling predicted an oral bioavailability of 90% and a half-life of 2 h in humans, which need to be verified in clinical trials.

Ritlecitinib Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

Ritlecitinib Suppliers

China 168 United States 8 Global 176

TargetMol Chemicals Inc.

Tel: +1-781-999-5354; +17819995354
Email: marketing@targetmol.com
Country: United States
ProdList: 32435
Advantage: 58

InvivoChem

Tel: +1-708-310-1919 +1-13798911105
Fax: 708-557-7486
Email: sales@invivochem.cn
Country: United States
ProdList: 6391
Advantage: 58

Cckinase, Inc.

Tel: +1 (732)236-3202
Email: sales@cckinase.com
Country: United States
ProdList: 2738
Advantage: 58

BOC Sciences

Tel: +1-631-485-4226
Fax: 1-631-614-7828
Email: inquiry@bocsci.com
Country: United States
ProdList: 19552
Advantage: 58

Aladdin Scientific

Tel
Email: tp@aladdinsci.com
Country: United States
ProdList: 57505
Advantage: 58

TargetMol Chemicals Inc.

Tel: +1-781-999-5354;
Email: support@targetmol.com
Country: United States
ProdList: 39035
Advantage: 58

United States Biological

Tel: --
Fax: --
Email: sales@advtechind.com
Country: United States
ProdList: 6075
Advantage: 58

United States Biological

Tel: --
Fax: --
Email: chemicals@usbio.net
Country: United States
ProdList: 6214
Advantage: 80

More

Less

View Lastest Price from Ritlecitinib manufacturers

Shaanxi Dideu New Materials Co. Ltd

Product: Ritlecitinib 1792180-81-4
Price: US $0.00-0.00/KG
Min. Order: 1KG
Purity: 98
Supply Ability: 10000KGS
Release date: 2025-12-01

Jinan Jianfeng Chemical Co., Ltd

Product: Ritlecitinib 1792180-81-4
Price: US $0.00-0.00/kg
Min. Order: 0.10000000149011612kg
Purity: 99%
Supply Ability: 5000kg
Release date: 2024-08-07

Dingwang Technology (Wuhan) Co., Ltd.

Product: Ritlecitinib 1792180-81-4
Price: US $0.00/g
Min. Order: 1g
Purity: 99% min
Supply Ability: 20 kg
Release date: 2024-08-20

1792180-81-4, RitlecitinibRelated Search:

PF-06700841 tosylate PF-06650833 PF-06447475 Lorlatinib (PF-06463922) 3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide 2-[[(2E)-3-(2-NAPHTHALENYL)-1-OXO-2-BUTEN-1-YL]AMINO]BENZOIC ACID Upadacitinib Q-VD-OPh hydrate N-(2-(4'-cyanobiphenyl-4-yl)propyl)propane-2-sulfonaMide H3B-6527 Senexin B 2-(2-((4-bromophenyl)amino)-2-oxoethoxy)-N-(2-(methyl(phenyl)amino)-2-oxoethyl)benzamide (S)-4-(4-((2-(3,5-diMethylphenyl)pyrrolidin-1-yl)Methyl)phenoxy)-3-fluorobenzaMide BMS-986205 Budiodarone tartrate COH-29

PF-06651600

EOS-61890

1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one

1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2

CS-2733

PF-06651600;PF 06651600;PF06651600

1-[(2S,5R)-2-methyl-5(7H-pyrrolo[2,3-d]pyrimidine-4-ylamino)-1-piperidinly]-2-propen-1-one malonate,PF06651600

Ritlecitinib

2-Propen-1-one, 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-

1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one

Ritlecitinib (PF-06651600)

Janus kinase,Inhibitor,inhibit,PF06651600,Ritlecitinib,JAK,PF 06651600

1-[(2S,5R)-5-[[7H-Pyrrolo[2,3-d]-4-pyrimidinyl]amino]-2-methyl-1-piperidyl]-2-propen-1-one

Ritlecitinib free base PF-06651600

Ritlecitinib, 10 mM in DMSO

Ritlectinib

Litaxitinib (base)

Litoxetine (base)

1792180-81-4

API

1